Physician profile
Joada J Best
NPI 1619153137
$4,350.45
in general payments reported to CMS, 2019-2025
22 companies · $620 in 2025
The $620 reported for 2025 was more than what a typical Psychiatric/Mental Health (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $762 · 2022: $1,134 · 2023: $1,110 · 2024: $725 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.47 |
| Education | $143.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $557.91 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $490.98 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $454.62 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $433.80 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $411.21 | 2021-2025 | Qelbree |
| Corium, LLC | $331.09 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $291.71 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $286.46 | 2021-2023 | Austedo Xr, Austedo |
| Lundbeck LLC | $205.87 | 2021-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $191.53 | 2021-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $158.76 | 2021-2024 | Fanapt, Hetlioz |
| Collegium Pharmaceutical, INC. | $146.93 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $115.72 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $47.64 | 2024 | Dyanavel Xr |
| Insulet Corporation | $45.48 | 2025 | Omnipod |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $43.46 | 2022-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $34.41 | 2022-2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $32.04 | 2025 | Cobenfy |
| Biohaven Pharmaceuticals, INC. | $25.78 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.31 | 2021 | |
| Eisai INC. | $15.11 | 2021 | |
| Axsome Therapeutics, INC. | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joada Best listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.